Organ-on-Chip & Organoids
CN Bio PhysioMimix
by CN Bio Innovations Ltd.
Scalable multi-organ-on-chip system for hepatotoxicity, DILI prediction, and NASH disease modeling
Category
Organ-on-Chip & Organoids
Founded
2009
Headquarters
Cambridge, United Kingdom
Overview
CN Bio Innovations produces the PhysioMimix organ-on-chip system, a microfluidic platform designed to culture human liver and multi-organ tissue models under physiologically relevant conditions. The system's MPS (Microphysiological Systems) technology recirculates culture media through liver tissue constructs — including primary human hepatocytes, Kupffer cells, and stellate cells — to maintain metabolic activity and zone-specific function for weeks. The PhysioMimix OOC platform includes single-organ and multi-organ configurations enabling gut-liver and lung-liver interaction studies. Drug developers and academic researchers use PhysioMimix primarily for drug-induced liver injury (DILI) prediction and non-alcoholic steatohepatitis (NASH) disease modeling — two areas where animal models notoriously underperform. The platform enables chronic dosing studies lasting 14-28 days, capturing cumulative hepatotoxicity that acute in vitro assays miss entirely. CN Bio has published extensive validation data demonstrating high sensitivity and specificity for known DILI compounds. CN Bio's focus on liver biology as a primary use case has allowed it to develop deep application expertise and validated assay workflows that generalist organ-on-chip platforms lack. The company offers PhysioMimix as both a research instrument and a contract research service, enabling pharma teams without internal microfluidics capability to access the technology through CRO partnerships. Its participation in FDA and IMI-funded MPS validation consortia has established PhysioMimix data as regulatorily relevant.
Key Features
Imaging & Analysis
Integrated confocal imaging and AI-powered image analysis for organoid phenotyping.
Toxicity Prediction
Predict organ-specific drug toxicity using human tissue models as alternatives to animal testing.
Bioprinting Integration
3D bioprinting of tissue constructs with controlled architecture and cellular composition.
Microfluidic Organ Chips
Recapitulate human tissue-level physiology in microfluidic devices for predictive drug testing.
Multi-Organ Systems
Connected organ chip models simulate drug ADME across multiple organ systems simultaneously.
Pros & Cons
Pros
- +Standardized culture protocols ensure reproducibility across labs and experimental batches
- +High-throughput organoid screening platforms test thousands of compounds per experiment
- +Reduces animal testing requirements while improving human-relevant toxicity predictions
- +Patient-derived organoids enable personalized drug screening for precision oncology applications
- +Multi-organ systems model drug absorption, distribution, metabolism, and excretion in vitro
- +Microfluidic organ chips recapitulate human tissue-level physiology for predictive drug testing
- +Real-time sensing and imaging capture dynamic tissue responses to drug exposure
Cons
- −Regulatory acceptance of organ-chip data as replacement for animal testing is still developing
- −High per-unit costs for microfluidic chips limit throughput compared to traditional cell culture
- −Current organ chips cannot fully recapitulate the complexity of whole-organ physiology
- −Organoid variability between batches and labs creates reproducibility challenges
Use Cases
Research Workflow Optimization
AI-powered optimization of research workflows to accelerate discovery timelines and improve reproducibility.
Data Analysis & Insights
Machine learning analysis of complex biological datasets to extract actionable insights and identify patterns.
Collaboration & Knowledge Management
Platform-enabled collaboration across distributed research teams with integrated data sharing and knowledge capture.